Schedule 13G ownership disclosure

CytomX Therapeutics Inc

Common Stock · CUSIP: 23284F105

Event date: 2025-06-30

Filing-level shares
9,379,794
Percent of class
5.95%
  • The Vanguard Group

    Shares: 9,379,794 · Class: 5.95%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000780
Form type
SCHEDULE 13G/A
Filer
CytomX Therapeutics, Inc.
CIK
CIK 1501989
Filed
Jul 29, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub